<DOC>
	<DOCNO>NCT02667275</DOCNO>
	<brief_summary>This randomize , double-blind , vehicle-controlled , parallel group study .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Vehicle-Controlled Study Subjects With Seborrheic Keratosis</brief_title>
	<detailed_description>This randomize , double-blind , vehicle-controlled , parallel group study . During study , investigator identify 4 eligible SK Target Lesions subject trunk , extremities face .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Keratosis , Seborrheic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Subject least 18 year age 2 . Clinical diagnosis stable clinically typical seborrheic keratosis 3 . Subject 4 appropriate seborrheic keratosis Target Lesions trunk , extremity face eligible treatment define : Have clinically typical appearance Have PLA 2 great discrete lesion Not cover hair , investigator 's opinion , would interfere study medication treatment study evaluation Not intertriginous fold Not eyelids Not within 5mm orbital rim Not pedunculated 4 . If subject woman childbearing potential , negative urine pregnancy test agree use active method birth control duration study 5 . Subject nonpregnant nonlactating 6 . Subject good general health free know disease state physical condition , investigator 's opinion , might impair evaluation Target Lesion expose subject unacceptable risk study participation 7 . Subject willing able follow study instruction attend study visit 8 . Subject able comprehend willing sign Informed Consent Form . 1 . Subject clinically atypical rapidly grow seborrheic keratosis lesion 2 . Subject presence multiple eruptive seborrheic keratosis lesion ( Sign Lesser Trelat ) 3 . Subject current systemic malignancy 4 . Subject use follow systemic therapy within specified period prior enrollment : Retinoids ; 180 day Glucocorticosteroids ; Antimetabolites ( e.g. , methotrexate ) ; 5 . Subject use follow topical therapy within specified period proximity Target Lesion , investigator 's opinion interferes study medication treatment study assessment : LASER , light energy base therapy ( e.g. , intense pulse light , photodynamic therapy ; Liquid nitrogen , electrodesiccation , curettage , imiquimod , 5flurouracil , ingenol mebutate ; Retinoids ; Microdermabrasion superficial chemical peel ; Glucocorticosteroids antibiotics 6 . Subject currently follow within specified period proximity Target Lesion , investigator 's opinion , interfere study medication treatment study assessment : A cutaneous malignancy ; A sunburn ; currently A premalignancy ( e.g. , actinic keratosis ) ; currently Body art ( e.g. , tattoo , piercing , etc . ) ; currently Excessive tan ; currently 7 . Subject history sensitivity ingredient study medication 8 . Subject current skin disease ( e.g. , psoriasis , atopic dermatitis , eczema , sun damage , etc . ) , condition ( e.g. , sunburn , excessive hair , open wound ) , opinion investigator , might put subject undue risk study participation interfere study conduct evaluation 9 . Subject participate investigational drug trial administration investigational study medication occur within 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>seborrheic keratosis</keyword>
</DOC>